目的 构建具有肿瘤细胞特异靶向性的纳米给药系统,研究该纳米粒的体外抗三阴乳腺癌作用。方法 采用乳化扩散溶剂挥发法制备包载奥拉帕尼的聚乙烯亚胺-聚乳酸-羟基乙酸共聚物(PEI-PLGA)纳米粒,进一步用透明质酸修饰,制备靶向载药纳米粒。采用激光粒度仪和透射电镜对纳米粒的形态、粒径大小、电位及分布情况进行表征。CCK-8法检测纳米粒对MDA-MB-231细胞的毒性作用,通过共聚焦显微镜观察细胞对目标纳米粒的靶向摄取,生物透射电镜观察细胞内部形态变化分析凋亡情况。结果 成功制备奥拉帕尼靶向载药纳米粒(HA-Ola-PPNPs),粒径为(166.2±0.842) nm,大小分布均匀,呈圆形或椭圆形,稳定性良好;奥拉帕尼包载于PEI-PLGA纳米粒中能够起到药物缓释作用;CCK-8实验结果显示纳米粒组均呈现出时间依赖和剂量依赖性细胞毒性,且HA-Ola-PPNPs对癌细胞具有更强的杀伤作用;激光共聚焦结果说明了HA与CD44受体的主动靶向结合可以显著提高MDA-MB-231细胞对目标纳米粒的摄取;生物透射电镜观察显示HA-Ola-PPNPs能够有效诱导MDA-MB-231细胞发生凋亡。结论 本研究成功制备了具有CD44受体特异性靶向的载药纳米粒,为三阴乳腺癌的临床治疗提供一种新策略。
Abstract
OBJECTIVE To synthesize the active-targeted olaparib-loaded polyethyleneimine-polyllactic-co-glycolic acid(PEI-PLGA) nanoparticles(HA-Ola-PPNPs) and investigate the therapy of triple negative breast cancer in vitro.METHODS The olaparib-loaded PEI-PLGA nanoparticles were prepared by the emulsion solvent diffusion evaporation method. And further modified with hyaluronic acid(HA) to prepare HA-Ola-PPNPs. The synthesis of HA-Ola-PPNPs was verified by dynamic light scattering(DLS) and transmission electron microscopy(TEM), the cytotoxicity was measured by CCK-8.Confocal microscopy was used to observe the uptake of NPs. Biological TEM was used to observe the morphological changes of cells and analyze the apoptosis.RESULTS The mean size of HA-Ola-PPNPs was (166.2±0.842)nm and showed negatively charged surface (-12.3±1.63)mV. The encapsulation efficiency of HA-Ola-PPNPs was (80.44±6.218)%. CCK-8 results showed that all the nanoparticles presented time-dependent and dose-dependent cytotoxicity, and HA-Ola-PPNPs exhibited efficient in vitro antitumor activities. The binding of HA to CD44 receptor could significantly improve the uptake of HA-Ola-PPNPs by MDA-MB-231 cells.And HA-Ola-PPNPs could effectively induce apoptosis of MDA-MB-231 cells.CONCLUSION In this study, active-targeted HA-Ola-PPNPs are successfully prepared, which could provide a new strategy for the clinical treatment of triple negative breast cancer(TNBC).
关键词
奥拉帕尼 /
纳米粒 /
透明质酸 /
三阴乳腺癌 /
主动靶向
{{custom_keyword}} /
Key words
olaparib /
nanoparticle /
hyaluronic acid /
triple-negative breast cancer /
active-target
{{custom_keyword}} /
中图分类号：
R944
R965
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] ABRAMSON V G, LEHMANN B D, BALLINGER T J, et al. Subtyping of triple-negative breast cancer: implications for therapy[J]. Cancer, 2015, 121(1): 8-16.
[2] JHAN J R, ANDRECHEK E R. Triple-negative breast cancer and the potential for targeted therapy[J]. Pharmacogenomics, 2017, 18(17): 1595-1609.
[3] CAREY L, WINER E, VIALE G, et al. Triple-negative breast cancer: disease entity or title of convenience[J]. Nat Rev Clin Oncol, 2010, 7(12): 683-692.
[4] JIN J, KRISHNAMACHARY B, MIRONCHIK Y, et al. Phototheranostics of CD44-positive cell populations in triple negative breast cancer[J]. Sci Rep, 2016, 6: 27871. Doi: 10.1038/srep27871.
[5] PANESAR S, NEETHIRAJAN S. Microfluidics: rapid diagnosis for breast cancer[J]. Nano Micro Lett, 2016, 8(3): 204-220.
[6] HENNEMAN L, VAN MILTENBURG M H, MICHALAK E M, et al. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer[J]. Proc Natl Acad Sci USA, 2015, 112(27): 8409-8414.
[7] GELMON K A, TISCHKOWITZ M, MACKAY H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study[J]. Lancet Oncol, 2011, 12(9): 852-861.
[8] BUNDRED N, GARDOVSKIS J, JASKIEWICZ J, et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery[J]. Invest New Drugs, 2013, 31(4): 949-958.
[9] MATEO J, MORENO V, GUPTA A, et al. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib[J]. Target Oncol, 2016, 11(3): 401-415.
[10] MAZZUCCHELLI S, TRUFFI M, BACCARINI F, et al. H-Ferritin-nanocagedolaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer[J]. Sci Rep, 2017, 7(1): 7505.
[11] SHI C, AHMAD K S, WANG K, et al. Improved delivery of the natural anticancer drug tetrandrine[J]. Int J Pharm, 2015, 479(1): 41-51.
[12] HU F Q, LIU L N, DU Y Z, et al. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles[J]. Biomaterials, 2009,30(36), 6955-6963.
[13] PERACCHIA M T, GREF R, MINAMITAKE Y, et al. PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: Investigation of their drug encapsulation and release characteristics[J]. J Controlled Release, 1997,46(3): 223-231.
[14] KELES H, NAYLOR A, CLEGG F, et al. Investigation of factors influencing the hydrolytic degradation of single PLGA microparticles[J]. Polym Degrad Stabil, 2015, 119: 228-241.Doi:10. 1016/j. polymdegradstab. 2015.04.025
[15] ZHANG Y, CUI Z, MEI H, et al. Angelica sinensis polysaccharide nanoparticles as a targeted drug delivery system for enhanced therapy of liver cancer[J]. Carbohydr Polym, 2019, 219: 143-154. Doi: 10. 1016/j. carbpol. 2019.04.041
[16] HUANG J, ZHANG H, YU Y, et al. Biodegradable self-assembled nanoparticles of poly(D,L-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer[J]. Biomaterials, 2014, 35(1): 550-566.
[17] SHI C, ZENG F, FU D. Surfactant-free poly(lactide-co-glycolide) nanoparticles for improving in vitro anticancer efficacy of tetrandrine[J]. J Microencapsul, 2016, 33(3): 249-256.
[18] EBRAHIMNEJAD P, DINARVAND R, SAJADI A, et al. Rad-Malekshahi, F. Atyabi, Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines[J]. Nanomedicine, 2010, 6(3): 478-485.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家自然科学基金项目资助(82073402)
{{custom_fund}}
PDF(3089 KB)
